Literature DB >> 7790024

Predominance of MHC class II-restricted CD4+ cytotoxic T cells against mouse hepatitis virus A59.

M H Heemskerk1, H M Schoemaker, W J Spaan, C J Boog.   

Abstract

Coronavirus-induced acute hepatitis is a complex event and the role of different components of the immune system with regard to defined viral proteins and the course of the infection is not yet clear. We have analysed the cytotoxic T-lymphocyte (CTL) response in mouse hepatitis virus (MHV-A59) infection. Surprisingly, we detected only a very clear virus-specific major histocompatibility complex (MHC) class II-restricted cytotoxicity in mice infected with MHV-A59. We found no evidence of activation of the classical CD8+ MHC class I-restricted CTL. The virus-specific CD4+ CTL derived from two different mouse strains having different MHC haplotypes recognized the same immunodominant epitope. This epitope, comprising the amino acid residues 329-343 of the viral S-glycoprotein, was recognized both at the polyclonal level and by virus-specific CTL clones. Transfer studies using a MHV-A59-specific CD4+ CTL clone showed significant protection against a lethal challenge with MHV-A59, implicating that these CD4+ CTL play a pivotal role in the protection against MHV-A59 infections.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7790024      PMCID: PMC1415158     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  36 in total

1.  Impaired intracellular transport of class I MHC antigens as a possible means for adenoviruses to evade immune surveillance.

Authors:  M Andersson; S Pääbo; T Nilsson; P A Peterson
Journal:  Cell       Date:  1985-11       Impact factor: 41.582

2.  Pathogenesis of demyelination induced by a mouse hepatitis.

Authors:  L P Weiner
Journal:  Arch Neurol       Date:  1973-05

3.  "Exon-shuffling" maps control of antibody- and T-cell-recognition sites to the NH2-terminal domain of the class II major histocompatibility polypeptide A beta.

Authors:  R N Germain; J D Ashwell; R I Lechler; D H Margulies; K M Nickerson; G Suzuki; J Y Tou
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

4.  Intracellular transport of recombinant coronavirus spike proteins: implications for virus assembly.

Authors:  H Vennema; L Heijnen; A Zijderveld; M C Horzinek; W J Spaan
Journal:  J Virol       Date:  1990-01       Impact factor: 5.103

5.  Hybridoma antibodies to the murine coronavirus JHM: characterization of epitopes on the peplomer protein (E2).

Authors:  H Wege; R Dörries; H Wege
Journal:  J Gen Virol       Date:  1984-11       Impact factor: 3.891

Review 6.  The biology and pathogenesis of coronaviruses.

Authors:  H Wege; S Siddell; V ter Meulen
Journal:  Curr Top Microbiol Immunol       Date:  1982       Impact factor: 4.291

7.  Cytotoxic T cell recognition of the influenza nucleoprotein and hemagglutinin expressed in transfected mouse L cells.

Authors:  A R Townsend; A J McMichael; N P Carter; J A Huddleston; G G Brownlee
Journal:  Cell       Date:  1984-11       Impact factor: 41.582

8.  Expression of class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells.

Authors:  P I Schrier; R Bernards; R T Vaessen; A Houweling; A J van der Eb
Journal:  Nature       Date:  1983 Oct 27-Nov 2       Impact factor: 49.962

9.  Isolation and identification of virus-specific mRNAs in cells infected with mouse hepatitis virus (MHV-A59).

Authors:  W J Spaan; P J Rottier; M C Horzinek; B A van der Zeijst
Journal:  Virology       Date:  1981-01-30       Impact factor: 3.616

10.  Temperature-sensitive mutants of mouse hepatitis virus strain A59: isolation, characterization and neuropathogenic properties.

Authors:  M J Koolen; A D Osterhaus; G Van Steenis; M C Horzinek; B A Van der Zeijst
Journal:  Virology       Date:  1983-03       Impact factor: 3.616

View more
  8 in total

1.  Differential activation of mouse hepatitis virus-specific CD4+ cytotoxic T cells is defined by peptide length.

Authors:  M H Heemskerk; H M Schoemaker; I De Jong; V E Schijns; W J Spaan; C J Boog
Journal:  Immunology       Date:  1995-08       Impact factor: 7.397

2.  Role of virus-specific CD4+ cytotoxic T cells in recovery from mouse hepatitis virus infection.

Authors:  O L Wijburg; M H Heemskerk; A Sanders; C J Boog; N Van Rooijen
Journal:  Immunology       Date:  1996-01       Impact factor: 7.397

3.  Mouse hepatitis virus infection of the CNS: a model for defense, disease, and repair.

Authors:  Chris S Schaumburg; Katherine S Held; Thomas E Lane
Journal:  Front Biosci       Date:  2008-05-01

4.  Cytotoxic T-lymphocyte precursor frequencies in BALB/c mice after acute respiratory syncytial virus (RSV) infection or immunization with a formalin-inactivated RSV vaccine.

Authors:  R A Tripp; L J Anderson
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

5.  Infection with cytotoxic T-lymphocyte escape mutants results in increased mortality and growth retardation in mice infected with a neurotropic coronavirus.

Authors:  L Pewe; S Xue; S Perlman
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

6.  Role of spleen macrophages in innate and acquired immune responses against mouse hepatitis virus strain A59.

Authors:  O L Wijburg; M H Heemskerk; C J Boog; N Van Rooijen
Journal:  Immunology       Date:  1997-10       Impact factor: 7.397

7.  Cooperation between transmissible gastroenteritis coronavirus (TGEV) structural proteins in the in vitro induction of virus-specific antibodies.

Authors:  I M Antón; S González; M J Bullido; M Corsín; C Risco; J P Langeveld; L Enjuanes
Journal:  Virus Res       Date:  1996-12       Impact factor: 3.303

8.  Identification of murine CD8 T cell epitopes in codon-optimized SARS-associated coronavirus spike protein.

Authors:  Yan Zhi; Gary P Kobinger; Heather Jordan; Katie Suchma; Susan R Weiss; Hao Shen; Gregory Schumer; Guangping Gao; Julie L Boyer; Ronald G Crystal; James M Wilson
Journal:  Virology       Date:  2005-04-25       Impact factor: 3.616

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.